DVHGF
Devonian Health Group Inc.
Save
24.78M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Similar securities
Based on sector and market capitalization
Report issue